University of Illinois Cancer Center member John Quigley, MD, was featured in June’s Big Ten Cancer Research Consortium’s newsletter highlighting his abstract presentation during the American Society of Clinical Oncology’s ASCO20 Virtual Scientific Program, which included more than 250 oral abstract presentations and 2,500 poster presentations from 24 disease-based and specialty tracks.
The BTCRC-AML17-113 poster provides safety and efficacy data for the Phase 1b study of gemtuzumab ozogamicin (GO) and venetoclax in patients with relapsed or refractory CD33+ acute myeloid leukemia. Quigley, associate professor of hematology and oncology at the University of Illinois College of Medicine, leads the study that is currently enrolling subjects at three Big Ten CRC member institutions.
“We are delighted ASCO reviewers have recognized the importance of this study by accepting it for publication at this year’s virtual meeting,” Quigley said in the CRC’s newsletter. “No major or unexpected toxicities were observed in Cohort 1.”
The goal of the study is to determine the maximum tolerated dose of venetoclax in combination with GO for this patient population. Researchers hypothesize venetoclax targeting of Bcl-2 proteins that protect AML stem cells from GO-inducted apoptosis will synergistically GO efficacy.
Quigley is a member of the UI Cancer Center’s Translational Oncology Program. Read abstract here.